New drug combo for rare blood disease under Long-Term safety watch
NCT ID NCT07413679
First seen Feb 22, 2026 · Last updated May 20, 2026 · Updated 17 times
Summary
This study looks at the long-term safety of adding danicopan to standard treatments (eculizumab or ravulizumab) for adults with PNH, a rare blood disorder. Researchers will track serious side effects and infections over time using registry data from 50 participants. The goal is to ensure the combination therapy remains safe for ongoing disease control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Alexion Pharmaceuticals, Inc. (Sponsor)
Boston, Massachusetts, 02210, United States
Conditions
Explore the condition pages connected to this study.